Meticulous Research®—a leading global market research company, published a research report titled ‘Saudi Arabia Next Generation Sequencing (NGS) Market Size, Share, Forecast, & Trends Analysis by Offering (Sample Preparation (DNA Extraction, Library Preparation), Instruments) Type (SMRT, DNB) Application (Clinical, Research) End User–Forecast to 2031. According to this latest publication from Meticulous Research®, the Saudi Arabia NGS market is expected to reach $50.0 million by 2031, at a CAGR of 10.1% from 2024 to 2031.

The growth of this market is driven by the rising number of cancer cases, increasing pharmaceutical R&D expenditures, and the surge in genome mapping programs are factors driving the growth of the Saudi Arabia NGS market. However, the high costs of NGS systems and consumables, data confidentiality concerns, the availability of alternative technologies, the low chances of identifying positive, actionable biomarkers, and ethical & legal issues related to NGS-based diagnosis restrain the growth of this market

In addition, increasing adoption of NGS tools among hospitals and clinical laboratories and government initiatives supporting large-scale genomic sequencing projects are expected to offer growth opportunities for market players. However, the shortage of skilled professionals, issues related to data storage, handling, interpretation, and confidentiality, and concerns about regulatory standards and standardization in diagnostic testing are some of the challenges impacting the market's growth.

Key Players:

Some of the key players operating in Saudi Arabia NGS market are Illumina, Inc. (U.S.), Thermo Fisher Scientific Inc. (U.S.), F. Hoffmann-La Roche Ltd. (Switzerland), Revvity, Inc. (U.S.), QIAGEN N.V. (Netherlands), Agilent Technologies, Inc. (U.S.), Pacific Biosciences of California, Inc. (U.S.), Danaher Corporation (U.S.), Oxford Nanopore Technologies Plc. (U.K.), Beijing Genomics Institute (BGI) (China), Bio-Rad Laboratories, Inc. (U.S.), and 10x Genomics, Inc. (U.S.).

How Vision 2031 Is Shaping NGS Adoption:

Saudi Arabia’s Vision 2031 isn’t just a policy document—it’s a comprehensive roadmap for the nation’s future. In healthcare, the vision is clear: build a world-class system that leverages the latest in medical science and technology. NGS fits perfectly into this picture.

Under Vision 2031, there’s a strong push for personalized medicine, where treatments are tailored to each patient’s genetic profile. The government is investing heavily in healthcare infrastructure, research, and public-private partnerships. This means more funding for hospitals, research centres, and biotech companies to adopt and implement NGS technologies.

NGS is already making a difference in areas like cancer diagnosis, rare genetic disorders, and infectious disease tracking. With Vision 2031’s backing, we can expect to see even broader adoption of NGS in routine clinical practice, research, and even public health initiatives. The ultimate goal? Better patient outcomes, more efficient healthcare delivery, and a stronger, knowledge-based economy.

Main Drivers Fueling NGS Market Growth in Saudi Arabia:

Rising Cancer Incidence: Cancer remains a leading cause of death in Saudi Arabia, with cases projected to rise from 28,113 in 2022 to 39,900 by 2030. NGS is increasingly adopted in oncology for early detection, therapy selection, and monitoring drug resistance, making it indispensable in modern cancer care.

Expanding Clinical Applications: Beyond oncology, NGS is gaining traction in reproductive health, Mendelian and complex disorders, and infectious disease diagnostics. The ability to simultaneously analyse hundreds of genes or entire genomes enables more accurate and comprehensive diagnoses.

Pharmaceutical & Biotech Sector Growth: The government’s biotechnology initiatives are fostering local R&D, leading to increased demand for NGS in drug discovery, translational research, and clinical trials. Pharmaceutical and biotechnology companies are expected to register the highest CAGR among end users during the forecast period.

Download Sample Report Here @ https://www.meticulousresearch.com/download-sample-report/cp_id=6002

Technological Advancements Shaping the NGS Industry:

Portable Sequencing Devices: The development of handheld, nanopore-based sequencers has made genetic testing more affordable, faster, and accessible—even outside traditional laboratory settings. These devices can sequence entire genomes for less than $1,000 and are being used for real-time disease characterization and population genomics.

Targeted Genome Sequencing: This technology, which offers low cost, quick results, and straightforward data analysis, is now the most widely adopted sequencing type in Saudi Arabia. It is especially valuable for identifying somatic mutations in cancer and other complex diseases.

Advances in Consumables and Reagents: Ongoing improvements in reagents, kits, and target enrichment protocols are driving the largest market segment—consumables—which accounted for 62.6% of the market share in 2024 and is projected to reach $50 million by 2031

Contact Us:
Meticulous Research®
Email- [email protected]
Contact Sales- +1-646-781-8004
Connect with us on LinkedIn- https://www.linkedin.com/company/meticulous-research